From Surf Wiki (app.surf) — the open knowledge base

Terbogrel

Terbogrel (INN) is an experimental drug that has been studied for its potential to prevent the vasoconstricting and platelet-aggregating action of thromboxanes. Terbogrel is an orally available thromboxane A2 receptor antagonist and a thromboxane A synthase inhibitor. The drug was developed by Boehringer Ingelheim.

A phase 2 clinical trial of terbogrel was discontinued due to its induction of leg pain.

References

(1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 37". WHO Drug Information.
(July 2004). "Pharmacokinetics and Pharmacodynamics of Terbogrel, a Combined Thromboxane A₂ Receptor and Synthase Inhibitor, in Healthy Subjects". British Journal of Clinical Pharmacology.
(October 2000). "Terbogrel, a Dual-Acting Agent for Thromboxane Receptor Antagonism and Thromboxane Synthase Inhibition". Acta Crystallographica.
(2014). "Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation". Journal of Thrombosis and Haemostasis.

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

antiplatelet-drugs 3-pyridyl-compounds guanidines nitriles tert-butyl-compounds

Want to explore this topic further?

Ask Mako anything about Terbogrel — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report